Search

Search bills, members, committees and pages...

Sign In

H.R. 4055

U.S. House•In House Committee

Summary

H.R. 4055, the Dialysis-Related Amyloidosis Treatment Act of 2025, was introduced in the House on Jun 20, 2025 by Rep. Brian Babin (R) with 2 co-sponsors. It was referred to Energy And Commerce, and last saw action on Jun 20, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Record

Text

H.R. 4055 has 2 co-sponsors.

hb4055/introduced-in-house.txt
119 HR 4055 IH: Dialysis-Related Amyloidosis Treatment Act of 2025
 U.S. House of Representatives
 2025-06-20
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 4055  IN THE HOUSE OF REPRESENTATIVES   June 20, 2025   Mr. Babin  introduced the following bill; which was referred to the  Committee on Energy and Commerce , and in addition to the Committee on  Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XVIII of the Social Security Act to provide coverage and payment under such title for certain treatments for dialysis-related amyloidosis, and for other purposes.
1.
Short title
This Act may be cited as the   Dialysis-Related Amyloidosis Treatment Act of 2025  .
2.
Coverage and payment for treatments for dialysis-related amyloidosis under the Medicare program
(a)
Coverage
Section 1861(s)(2) of the Social Security Act ( 42 U.S.C. 1395x(s)(2) ), is amended—
(1)
in subparagraph (JJ), by inserting  and  at the end; and
(2)
by adding at the end the following new subparagraph:
(KK)
treatments for dialysis-related amyloidosis (as defined in subsection (nnn));
 .
(b)
Treatments for dialysis-Related amyloidosis defined
(1)
In general
Section 1861 of the Social Security Act ( 42 U.S.C. 1395x ), is amended by adding at the end the following new subsection:
(nnn)
Treatments for dialysis-Related amyloidosis
The term  treatments for dialysis-related amyloidosis  means any item or service that is furnished in a dialysis facility (freestanding or hospital-based) that is approved by the Food and Drug Administration for the treatment of dialysis-related amyloidosis, and any supplies or services that are provided adjunct to and are necessary for such treatment.
 .
(2)
Exclusion from renal dialysis services
Section 1881(b)(14)(B) of the Social Security Act ( 42 U.S.C. 1395rr(b)(14)(B) ) is amended by inserting before the period at the end the following:  or  treatments for dialysis-related amyloidosis  (as defined in section 1861(nnn)) .
(c)
Payment
Section 1833(a)(1)(E) of the Social Security Act ( 42 U.S.C. 1395l(a)(1)(E) ) is amended by inserting at the end the following:  except for treatments for dialysis-related amyloidosis, which may not be included as a renal dialysis service for purposes of payment under any prospective payment amount or comprehensive fee established under section 1881, and for which payment shall be made separately in the amount of 100 percent of the reasonable charges for such items and services, .
(d)
Effective date
The amendments made by this section shall take effect on the date of the enactment of this Act.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-06-20
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To amend title XVIII of the Social Security Act to provide coverage and payment under such title for certain treatments for dialysis-related amyloidosis, and for other purposes.

Sponsors

Rep. Brian Babin (R) sponsors H.R. 4055, and 2 members have co-sponsored it.

Committees

H.R. 4055 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means
Ways and Means
Referred To · Jun 20, 2025 · 1,160 Bills
Energy and Commerce
Energy and Commerce
Referred To · Jun 20, 2025 · 1,636 Bills

Actions

H.R. 4055 has taken 2 actions since Jun 20, 2025.

ChamberAction
Jun 20, 2025
House
Introduced in House
Jun 20, 2025
House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 4055 has not gone to a roll call.

Titles

H.R. 4055 goes by 3 titles, 1 of them short titles.

  • Dialysis-Related Amyloidosis Treatment Act of 2025 — Display Title
  • Dialysis-Related Amyloidosis Treatment Act of 2025 — Short Title(s) as Introduced
  • To amend title XVIII of the Social Security Act to provide coverage and payment under such title for certain treatments for dialysis-related amyloidosis, and for other purposes. — Official Title as Introduced

Lobbying

1 client hired 1 firm and 2 registered lobbyists who named H.R. 4055 in 2 quarterly filings, 2025. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Medicare/Medicaid.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
KANEKA PHARMA AMERICA, LLCDistributor of life science systemsCalifornia12$70K

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
KING & SPALDING LLP12$70K

Lobbyists

Named on the filings that cite the bill.

LobbyistFirmsClientsFilings
DAVID FARBER112
SCOTT DZIENGELSKI112

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
KANEKA PHARMA AMERICA, LLCKING & SPALDING LLP2025 fourth_quarter$40K4th Quarter - Termina…
KANEKA PHARMA AMERICA, LLCKING & SPALDING LLP2025 third_quarter$30K3rd Quarter - Report

Classification

The Congressional Research Service files H.R. 4055 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 4055’s is Health.

hr4055/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com